Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pathology Checklist a First for Next Generation Sequencing Laboratory Standards

By LabMedica International staff writers
Posted on 20 Aug 2012
A gold standard molecular pathology checklist has been revised to include a dedicated section on next generation sequencing (NGS), the first published laboratory accreditation checklist that addresses NGS, advancing standardized practice in genomic testing.

The College of American Pathologists (CAP; Northfield, IL, USA), the largest association of board-certified pathologists and a global leader in laboratory quality assurance, has now published the new edition of the CAP Laboratory Accreditation Program checklists, released July 31, 2012. More...
CAP checklists are used to guide accreditation of more than 7,000 laboratories in the US and abroad.

“Pathologists, trained to provide medical direction of NGS testing, and the CAP, experienced in laboratory quality assurance programs, are not only leading this NGS initiative, but collaborating with other medical organizations to advance the science of genomic medicine,” said Karl V. Voelkerding, MD, FCAP, professor of Pathology at the University of Utah, and Medical Director for Genomics and Bioinformatics at ARUP Laboratories (Salt Lake City, UT, USA). Dr. Voelkerding led the CAP working group that created the NGS section of the molecular pathology checklist. The new NGS section has 18 requirements that address the analytical wet bench process including conversion of DNA into a NGS library followed by sequencing, and the subsequent bioinformatics analyses comprised of sequence alignment and mapping, variant calling, and annotation.

“The publication of this checklist demonstrates CAP’s leadership in advancing standards of practice in genomic medicine,” said Nazneen Aziz, PhD, director of Molecular Medicine and staff lead for the CAP’s NGS Working Group. “The workgroup was judicious in developing the requirements by creating the necessary framework for clinical testing using NGS and yet not being overly prescriptive to accommodate the differences in the technology platforms and the growth of the rapidly evolving technology”.

The CAP’s efforts to further advance clinical testing using NGS go beyond accreditation and will include development of NGS proficiency testing products in the near future. The CAP supports and continues to work with other organizations, including the American College of Medical Genetics and Genomics (ACMG), the Association for Molecular Pathology (AMP), and Health Level 7 (HL-7), to develop standards for reporting genetic variants, for their interpretation for clinical use and interoperability of results in healthcare information systems.

Related Links:

College of American Pathologists
ARUP Laboratories




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.